ENTERA BIO LTD. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
ENTERA BIO LTD. (ENTX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$2.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-27
- ENTERA BIO LTD. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$2.63M.
- ENTERA BIO LTD. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$2.20M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$2.63M 10-K · filed 2026-03-27 |
| 2024-12-31 | -$2.20M 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |